The bioassay services market for cell therapy and gene therapy is expected to reach USD 155 million in 2021 anticipated to grow at a CAGR of 30.1% during the forecast period 2021-2032

The preference for cell and gene therapies in addressing severe medical conditions has led to a significant increase in their development and approval for treating various diseases. Currently, more than 30 therapies have been approved, with over 1,200 in different stages of development. This rise in favorability positions these advanced therapies to potentially become a highly esteemed segment in the biopharmaceutical industry.
Despite their potential, developing cell and gene therapies is complex and financially demanding. Consequently, outsourcing has become a favored approach, with companies relying heavily on specialized service providers to handle different aspects of their product development and manufacturing. The majority of biopharmaceutical companies prefer outsourcing, with a significant portion of their spending directed towards these services. Analytical testing services, including various types of testing like environmental, bioanalytical, chemistry, stability testing, method development, validation, and product characterization, have seen a notable surge in demand.
This increased demand for outsourcing analytical testing services has led to the emergence of specialized contract research organizations focusing on offering tailored bioassay services for cell and gene therapies. These organizations possess advanced technology and expertise, aiding in study optimization, cost efficiency, and timeline reduction. With ongoing efforts to enhance their offerings, the market for cell and gene therapy bioassay services is expected to consistently grow in the forecasted period.

Report Coverage
? Detailed overview of the global cell & gene therapy bioanalytical testing services market, including company details (year of establishment, size, HQ, facilities), offerings (in vitro, in vivo), bioassay types, services offered (immunoassay, PCR, flow cytometry, etc.), and applications (cell therapy, gene therapy).
? Competitive analysis of bioassay service providers globally, considering service strength, applicability, and supplier experience.
? Profiles of key players in North America, Europe, and Asia-Pacific offering cell and gene therapy bioassay services, covering company overview, service portfolio, offerings, bioassay types, facilities, recent developments, and future outlook.
? Market trend analysis of cell and gene therapy service providers based on offered services and application areas, with a map showing bioanalytical facility locations.
? Analysis of global events attended by service providers, focusing on service types, application areas, and strategic initiatives.
? Case study of the cell and gene therapy market landscape, including distribution by development phase, therapeutic areas, and developer types.
? In-depth analyses of 260 cell therapy developers and 190 gene therapy developers anticipated to partner with bioassay service providers, based on company strength, pipeline maturity, and capabilities.

Key Market Companies
? CCRM
? Nexelis
? Pacific BioLabs
? PPD Laboratories
? WuXi Advanced Therapies
? AnaBioTec
? Intertek Pharmaceutical Services
? Lonza
? Porton Bio